title: Differential involvement of MEK kinase 1 (MEKK1) in the induction of apoptosis in response to microtubule-targeted drugs versus DNA damaging agents.
abstract: MEK kinase 1 (MEKK1) is a 196-kDa enzyme that is involved in the regulation of the c-Jun N-terminal kinase (JNK) pathway and apoptosis. In cells exposed to genotoxic agents including etoposide and cytosine arabinoside, MEKK1 is cleaved at Asp874 by caspases. The cleaved kinase domain of MEKK1, itself, stimulates caspase activity leading to apoptosis. Kinase-inactive MEKK1 expressed in HEK293 cells effectively blocks genotoxin-induced apoptosis. Treatment of cells with taxol, a microtubule stabilizing agent, did not induce MEKK1 cleavage in cells, and kinase-inactive MEKK1 expression failed to block taxol-induced apoptosis. MEKK1 became activated in HEK293 cells exposed to taxol, but in contrast to etoposide-treatment, taxol failed to increase JNK activity. Taxol treatment of cells, therefore, dissociates MEKK1 activation from the regulation of the JNK pathway. Overexpression of anti-apoptotic Bcl2 blocked MEKK1 and taxol-induced apoptosis but did not block the caspase-dependent cleavage of MEKK1 in response to etoposide. This indicates Bcl2 inhibition of apoptosis is, therefore, downstream of caspase-dependent MEKK1 cleavage. The results define the involvement of MEKK1 in the induction of apoptosis by genotoxins but not microtubule altering drugs.
authors: Program in Molecular Signal Transduction, Division of Basic Sciences, National Jewish Medical and Research Center, Denver, Colorado, 80206, USA.
authors: S
authors: S
authors: Gibson
authors: C
authors: C
authors: Widmann
authors: G L
authors: GL
authors: Johnson
mesh_terms: D017209:Apoptosis / Q000187:drug effects* / Q000502:physiology; D002460:Cell Line; D003561:Cytarabine / Q000494:pharmacology; D004249:DNA Damage; D004789:Enzyme Activation; D005047:Etoposide / Q000494:pharmacology; D006801:Humans; D006868:Hydrolysis; D048728:MAP Kinase Kinase Kinase 1; D008870:Microtubules / Q000187:drug effects*; D009153:Mutagens / Q000494:pharmacology*; D017239:Paclitaxel / Q000494:pharmacology; D017346:Protein Serine-Threonine Kinases / Q000502:physiology*; D019253:Proto-Oncogene Proteins c-bcl-2 / Q000378:metabolism / Q000502:physiology; D014747:Vinblastine / Q000494:pharmacology
chemical_list: D009153:Mutagens; D019253:Proto-Oncogene Proteins c-bcl-2; D003561:Cytarabine; D014747:Vinblastine; D005047:Etoposide; D017346:Protein Serine-Threonine Kinases; D048728:MAP Kinase Kinase Kinase 1; C482576:MAP3K1 protein, human; D017239:Paclitaxel